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Background: There is increasing autonomy among emergency physicians diagnosing
patients with STEMIs but little is known about the factors that influence the time
required to establish this diagnosis. We hypothesize that the time from hospital arrival
to STEMI diagnosis (door to activation time, D2A) constitutes the greatest source of
variability on door-to-balloon (D2B) time in contemporary practice.
Methods: Registry data on 407 patients diagnosed with a STEMI in the emergency
department (ED) over 30 months at two primary PCI centers were analyzed using
multivariate regression models. The primary outcome was time from hospital arrival
to STEMI diagnosis by the emergency department physician.
Results: The median D2A time was 21 minutes (IQR 9 – 57). Among component parts
of the D2B time, variation in D2A times explained 90.5% of the variation in D2B times
and demonstrated the strongest correlation with D2B times (correlation coefficient
0.945). Significant predictors of D2A time include: pre-hospital ECG use (63% shorter,
95%CI -50 to -72%, p <0.001) and CT scan use in the ED (202% longer, 95%CI +34
to +305%, p = 0.001). The consequent D2B times were 19% shorter (95%CI -8 to -
29%, p = 0.001) and 83% longer (95%CI +46 to + 227%, p <0.001) respectively.
Scatter plot of correlation between door to activation time and door to balloon time.
Circles are individual subjects with fitted regression line in red. X & Y axes are log
scale.
Conclusion: The majority of the variability in D2B times is the result of time spent
establishing the diagnosis of a STEMI. Adoption of best practice techniques have led
to broadly improved D2B times, but most current strategies presume a prompt STEMI
diagnosis and pay little attention to improving clinical decision making. Our data
suggests that establishing a STEMI diagnosis is, in fact, the primary source of the
inconsistencies in D2B times remaining in contemporary practice.
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Background: Patients with STEMI are among the highest risk for intraprocedural
thrombotic events (IPTE) due to the presence of plaque rupture with high thrombus
burden within the culprit coronary artery. While IPTE increase procedural complexity,
it is unknown to what extent adverse angiographic events encountered during STEMI
PCI are associated with late clinical outcomes.
Methods: 3163 patients who underwent primary PCI for STEMI in the HORIZONS-
AMI trial underwent detailed frame-by-frame core lab angiographic analyses. IPTE
events were correlated with clinical outcomes.
Results: A total of 386 patients (12.2%) had an IPTE, which consisted of new or
increasing thrombus (40.9%), abrupt vessel closure (19.2%), no reflow (16.6%), slow
flow (36.8%), or distal embolization (36.0%). Patients with IPTE were similar to
patients without IPTE in most baseline clinical characteristics, although PCI of the
LAD was more often performed in patients with IPTE (45.6% vs. 40.2%, p=0.037).
Patients with IPTE also were more frequently randomized to bivalirudin compared to
heparin+GPIIb/IIIa inhibition (p=0.025). Compared to patients without IPTE, patients
experiencing IPTE had significantly greater rates of composite ischemic events, non-
CABG major bleeding, and overall mortality at 30 days and 3 years (Table).
Conclusion: The occurrence of IPTE in patients treated with primary PCI for STEMI
was strongly associated with subsequent early and late adverse outcomes including
composite ischemia, major bleeding, and death.
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Background: Stent thrombosis (ST) remains a major concern with STEMI patients
treated with primary PCI.
Methods: Consecutive patients (n=1640) undergoing stenting for STEMI were
prospectively enrolled in our database. BMS were implanted from 1995-2002, and
both BMS and DES were implanted form 2002-2010. Patients were followed for 1-15
years. ST was defined as ARC definite or probable.
Results: Our pt population had a high risk profile including a high incidence of killip
class III-IV (11.5%) and STEMI due to ST (10.2%). ST occurred in 132 pts including
85 with early or late ST and 47 with very late ST. The frequency of ST was 3.2% at 30
days, 5.7% at 1 yr and 8.8% at 5 yrs (Figure). Killip Class III-IV, small stent diameter,
STEMI due to ST, early reperfusion, and prior infarction were independent predictors
of early or late ST (Table). DES was the only independent predictor of very late ST.
Multivariable Predictors of Early or Late and Very Late ST
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Conclusion: ST after primary PCI is frequent and continues to increase past 5 years.
New strategies are needed to prevent ST in STEMI patients, and targeted therapies are
needed in patients identified at highest risk.
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Background: The incidence and outcome of pts undergoing stent thrombosis (ST)
post drug-eluting stents (DES) implantation remains controversial. We report the long-
term follow-up (FU) of pts with ST post implantation of DES in the real-world clinical
practice.
Methods: The DESIRE Registry is a large, prospective, non-randomized clinical trial
evaluating the long-term clinical FU of pts undergoing elective or urgent percutaneous
coronary intervention (PCI) with DES as the default strategy in a single center. From
05/02 to 05/11, 3,694 pts (5,568 lesions) were treated with 5,615 DES. Clinical FU
was performed at 1, 6 and 12 months, and annually up to 9 years (median = 4,2 years).
ST was defined according to the Academic Research Consortium criteria.
Results: During the late clinical FU (completed in 98%), the overall incidence of ST
was 1.9% (n=69) given that 97% of patients were free from this event at 9 years. A
total of 40 cases (58%) were classified as definite ST (with angiographic confirmation).
The mean time from index procedure to the occurrence of definite ST was 1.9±1.7
years [34 cases in the very late phase (>1 year)]. Independent predictors of ST were
acute MI (HR 3.14, p<0.01), current smoking (HR 2.05, p=0.03), multiple DES
implanted (HR 2.11, p=0.003), lesion postdilatation (HR 0.51, p=0.02), significante
lesion calcification (HR 2.01, p=0.01), and in-stent residual stenosis by QCA (HR 1.04,
p<0.001).
Conclusion: In this large, prospective “real-world” registry, unselected patients
undergoing DES implantation had low cumulative incidence of ST (1.9%), and 97%
of patients were free from ST up to 9 years. Overall, the majority of ST occurred >12
months and were classified as definite ST (according to the ARC definition).
Significant predictors of ST were: current smoking, diabetes, PCI in the setting of acute
MI, multiple stenting implantation, balloon postdilata-tion, lesion complexity and stent
underexpansion
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Background: Clinical implication of positive peristent vascular remodeling (PPVR)
after drug-eluting stent(DES) implantation is not well defined.
Methods: The POET study was a multicenter, randomized trial which enrolled patients
with stable or unstable angina. A total 226 patients (SES: n= 105, PES: n= 121) who
underwent post-intervention and 9-month follow-up intravascular ultrasound analysis
were followed clinically for 5 years. PPVR was arbitrarily defined as >10% increase
in external elastic membrane volume index at follow-up. We investigated long-term
outcomes of the patients according to the presence of PPVR at 9 months.
Results: Percent neointimal volume obstruction at follow-up was significantly smaller
with SES than with PES (1.9±3.5% vs. 9.6±9.8%, p<0.001). However, PPVR (38%
vs. 24%, p=0.019), and late acquired stent malapposition (LASM) (18% vs. 9%,
p=0.034) occurred more frequently with SES than with PES. Unstable angina [odd
ratio (OR)= 3.62(1.97-6.65), p < 0.001] and SES [OR = 1.86(1.03-3.38), p = 0.041]
were independent risk factors of PPVR. The cumulative incidence of major adverse
cardiac events at 5 years did not differ between the patient groups with and without
PPVR. However, stent thrombosis (ST) was observed more frequently in patients with
PPVR than those without PPVR (8.5% vs. 1.3%, p=0.007). The occurrence of ST did
not differ between SES and PES (3.8% vs. 3.3%, p=0.838).
Conclusion: PPVR and LASM were found more frequently with SES than PES,
although the rate of ST did not differ significantly between the two DES types.
However, patients who developed PPVR after implantation of DES experienced more
frequently late or very late ST compared to those without PPVR. PPVR appears to be
an important risk factor of late or very late ST.
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Background: Stent thrombosis (ST) is an increasing cause of STEMI, but outcomes
with STEMI due to ST vs de novo coronary artery occlusion have not been well
characterized.
Methods: From 2003-2010, 3305 consecutive pts with STEMI treated with primary
PCI at Minneapolis Heart Institute (n=2086) and Cone Heart and Vascular Center
(n=1219) were prospectively enrolled in our Registry. Outcomes were evaluated with
Kaplan Meier estimates and Cox Regression.
Results: Stent thrombosis (ST) accounted for 8.5% (282/3305) of all STEMIs with
the proportion increasing from 4.9% in 2003 to 9.9% in 2010. DES accounted for 31%
of STEMI due to ST in 2003, increasing to 75% in 2006 and decreasing to 60% in
2009-10. Pts with ST vs de novo coronary artery occlusion had more diabetes,
hypertension, prior MI, and prior CABG and had lower LVEF and a higher frequency
of occluded infarct artery on initial angiography. Pts with ST had similar hospital
mortality (5.3% vs 4.6%, p=0.55) but more hospital re-infarction (3.9% vs 1.2%,
p=0.004), and at 5 years had more re-infarction ( 21.8% vs 10.0%, p<0.001) and more
death or re-infarcton (35.7% vs 22.8%, p<0.001). After adjusting for differences in
baseline risk, STEMI due to ST compared with de novo occlusion was an independent
predictor of late re-infarction (HR 2.79 95% CI 1.92-4.03, p<0.001) and late death or
re-infarction (HR 1.55, 95% CI 1.17-2.04, p=0.002).
Conclusion: Stent thrombosis accounts for an increasing proportion of STEMI pts and
is associated with worse outcomes compared with de novo coronary artery occlusion.
New strategies are needed to address this growing problem.
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